8-K: Sanara MedTech Enters Exclusive License and Distribution Agreement with Biomimetic Innovations, Invests for 12.5% Equity Stake

Sanara MedTech secures exclusive U.S. rights to OsStic bone void filler and related technologies from Biomimetic Innovations, accompanied by a minority equity investment.

Summary

• Sanara MedTech Inc. has entered into an exclusive licensing and distribution agreement with Biomimetic Innovations Ltd (BMI) for OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler and related technologies.
• Sanara gains exclusive U.S. marketing, sales, and distribution rights for trauma indications for an initial five-year term, with potential for automatic two-year renewals.
• The agreement includes an option for Sanara to negotiate exclusive distribution rights in additional fields and territories.
• Sanara will pay BMI quarterly royalties based on a percentage of Net Sales Value, with the percentage for OsStic in the mid-single digit range.
• Minimum royalty payments in the low to mid six figure range are required for the first three years following regulatory approval.
• Sanara is investing up to $8.0 million in BMI for approximately 12.5% of its outstanding equity.
• An initial investment of $4.0 million has been made, including the conversion of a $1.0 million convertible loan.
• The remaining $4.0 million is contingent upon achieving certain development, clinical, and regulatory milestones.
• Sanara's Chief Corporate Development & Strategy Officer, Tyler Palmer, has been appointed to BMI's board of directors.
• Sanara anticipates introducing OsStic to the U.S. market in the first quarter of 2027.
• OsStic has received FDA Breakthrough Device Designation for use in periarticular fractures or defects.

Sentiment

Score: 7

Explanation: The announcement is positive due to the exclusive licensing agreement, FDA designation, and potential market opportunity. However, the long lead time to market and investment risks temper the overall sentiment.

Positives

• Exclusive U.S. distribution rights for OsStic provide Sanara with a potentially valuable asset.
• FDA Breakthrough Device Designation for OsStic could expedite regulatory review and market access.
• Investment in BMI provides Sanara with equity upside and influence over product development.
• OsStic is expected to complement Sanara's existing surgical product portfolio.
• The agreement aligns with Sanara's focus on improving patient outcomes and reducing healthcare costs.
• The agreement targets an estimated 100,000+ procedures in the U.S. annually.

Negatives

• Sanara is investing a significant amount of capital ($8.0 million) in BMI, with the remaining $4.0 million contingent on milestones.
• The launch of OsStic in the U.S. is not expected until the first quarter of 2027, creating a long lead time for revenue generation.
• The success of OsStic depends on obtaining regulatory clearance from the FDA.
• Royalty payments to BMI will impact Sanara's profitability on OsStic sales.
• Minimum royalty payments in the low to mid six figure range are required for the first three years following regulatory approval, regardless of sales.

Risks

• Regulatory approval for OsStic may be delayed or not granted.
• The development, clinical, and regulatory milestones required for the remaining $4.0 million investment may not be achieved.
• Market acceptance of OsStic may be lower than anticipated.
• Competition from existing bone void fillers and other fracture management technologies could limit OsStic's market share.
• The relationship with BMI could deteriorate, impacting the distribution agreement.
• The company may not be able to effectively integrate OsStic into its existing surgical product portfolio.

Future Outlook

Sanara anticipates introducing OsStic to the U.S. market in the first quarter of 2027 and expects it to complement their existing surgical product portfolio, enhancing patient outcomes and reducing healthcare costs.

Management Comments

• Ron Nixon, Sanara's Executive Chairman and CEO, stated that OsStic offers a truly differentiated solution designed to enhance the fracture repair process and represents a compelling treatment option for periarticular fractures.
• Dr. Thomas Russell, Chief Medical Officer of PBC Biomed, stated that OsStic sets a new standard with its innovative formulation, optimizing fluidic dispersion, interdigitating with the surrounding boney structure, and firmly adhering to bone surfaces.
• Paul Burke, Managing Partner of PBC Biomed Ltd and acting CEO of Biomimetic Innovations stated, that Sanara represents an ideal partner to commercialize their innovative technologies.

Industry Context

The agreement positions Sanara to compete in the bone void filler market, addressing an estimated 100,000+ procedures annually in the U.S. The FDA Breakthrough Device Designation for OsStic could provide a competitive advantage.

Comparison to Industry Standards

• Zimmer Biomet acquired CelgenTek Innovations in 2016, which brought the N-Force Fixation/iN3 Cement to market, demonstrating the value of innovative bone repair technologies.
• Mochida Pharmaceuticals Ltd partnered with PBC Biomed to bring ReFeel to market as a nerve regeneration solution, highlighting the potential for partnerships in the medical device space.
• Traditional calcium phosphate bone substitute materials offer basic bone void filling properties, but OsStic is engineered to optimize fluidic dispersion into bone defects, interdigitate with the surrounding boney structure, and firmly adhere to bone surfaces.

Stakeholder Impact

• Shareholders: The agreement could positively impact shareholder value through increased revenue and market share.
• Employees: The agreement may create new job opportunities within Sanara's sales and marketing teams.
• Customers: Surgeons and clinicians will have access to a new bone void filler technology.
• Patients: OsStic could improve patient outcomes in fracture management.
• Suppliers: The agreement may lead to increased demand for Sanara's existing surgical products.

Next Steps

• Sanara will work towards obtaining regulatory clearance for OsStic from the FDA.
• The company will integrate OsStic into its existing surgical product portfolio.
• Sanara will continue to monitor the development, clinical, and regulatory milestones required for the remaining $4.0 million investment in BMI.
• Sanara will prepare for the anticipated launch of OsStic in the U.S. market in the first quarter of 2027.

Key Dates